Pharmaceuticals, Biotechnology & Life Sciences

Pfizer’s latest SEC filing reveals CEO ownership changes, highlights strong market gains, and shows executive mobility—offering investors a clear view of compliance, performance, and industry shifts.

Explore how Novo Nordisk’s new drugs Frehemgo and Zaltenibart are redefining rare haemorrhagic care—boosting patient convenience, cutting costs, and driving high‑margin growth.

Innate Pharma extends 2028 cash runway with Sobi partnership and €30 M raise, launching lacutamab in CTCL while diversifying with IPH4502 and monalizumab.

MTI’s stock jumps above its 200‑day moving average, signaling a modest investor‑sentiment lift amid stable fundamentals. Check the latest outlook.

Discover how Astellas Pharma’s partnership fuels a faster, cost‑effective oncology pipeline, boosting value‑based care and investor confidence in 2024‑25.

German equities edge up on September 16 as oil falls and bond yields rise, but Qiagen slips amid cost pressures and geopolitical uncertainty.

Takeda’s latest SEC filing shows a senior officer increasing his stake to 191,000 shares, confirming continued executive ownership and stability.

Galderma’s promising Restylane Volyme results in China signal a high‑margin growth path amid patent cliffs, competitive pressures, and M&A opportunities.

ARGENX SE’s September 17 EGM will reveal new BCL‑2 and PI3K drug updates, governance changes, and market plans – a must‑watch for investors and pharma analysts.

Discover how United Therapeutics’ insider trades reveal governance strength and strategic moves to master value‑based reimbursement, cost‑efficiency, and supply‑chain resilience for cutting‑edge biotech therapies.